Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 220S220 trades$52.89M
Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Pulliam Viktoryia G.SVP of Accounting |  GDENNEW ROYAL HOLDCO I INC.Option exercise | M | — 2,388 sh | Apr 30, 2026 |
| 9 | Flores James CaldwellPresident, COO |  SOCSable Offshore Corp.Option exercise | M | — 100.0K sh | Apr 30, 2026 traded Apr 29, 2026 |
| 9 | Antonijevic IrinaDirector |  BHVNBiohaven Ltd.Grant or award | A | — 68.7K sh | Apr 30, 2026 traded Apr 28, 2026 |
| 9 | Gilson Jean-MarcDirector |  CTVACorteva, Inc.Grant or award | A | — 2,350 sh | Apr 30, 2026 traded Apr 28, 2026 |
| 9 | Brandman JaredChief Legal & Strategy Officer |  EYENational Vision Holdings, Inc.Option exercise | M | — 1,890 sh | Apr 30, 2026 traded Apr 29, 2026 |
| 9 | Burks DerrickDirector |  ELSEQUITY LIFESTYLE PROPERTIES INCGrant or award | A | $20K 319 sh | Apr 30, 2026 traded Apr 28, 2026 |
| 9 | Hollin Edward J.Director |  MRBKMeridian CorpOption exercise | M | $2,600 200 sh | Apr 30, 2026 traded Apr 29, 2026 |
| 9 | van Houte HansChief Financial Officer |  NRIXNurix Therapeutics, Inc.Option exercise | M | — 3,750 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 9 | Klang Lisa Marie ThomsonChief Accounting Officer |  PSNYPolestar Automotive Holding UK PLCGrant or award | A | — 2,161 sh | Apr 30, 2026 traded Apr 28, 2026 |
| 9 | Patrinely Gregory D.EVP, CFO | SOCSable Offshore Corp. Option exercise | M | — 100.0K sh | Apr 30, 2026 traded Apr 29, 2026 |
| 9 | Dozier AnnDirector | GDENNEW ROYAL HOLDCO I INC. Disposition to issuer | D | — 51.6K sh | Apr 30, 2026 traded Apr 30, 2026 |
| 9 | Pulliam Viktoryia G.SVP of Accounting | GDENNEW ROYAL HOLDCO I INC. Disposition to issuer | D | — 5,010 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 9 | Mehta KishanDirector | BHVNBiohaven Ltd. Grant or award | A | — 68.7K sh | Apr 30, 2026 traded Apr 28, 2026 |
| 9 | Hollin Edward J.Director | MRBKMeridian Corp Option exercise | M | — 200 sh | Apr 30, 2026 traded Apr 29, 2026 |
| 6 | Remer Eric RichardDirector, Chief Executive Officer |  EVCMEverCommerce Inc.Open-market sale · 10b5-1 plan | SELL | $66K 5,567 sh | Apr 30, 2026 traded Apr 28, 2026 |
| 6 | Ring ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 6 | Remer Eric RichardDirector, Chief Executive Officer | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $89K 7,766 sh | Apr 30, 2026 traded Apr 29, 2026 |
| 6 | Ring ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 6 | Remer Eric RichardDirector, Chief Executive Officer | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $67K 5,867 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 6 | Ring ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 6 | Ring ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Ladd Amy LDirector | ISRGINTUITIVE SURGICAL INC Grant or award | A | — 554 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Mark & Robyn Jones Descendants Trust 201410% Owner, Member of 10% owner group |  GSHDGoosehead Insurance, Inc.Derivative conversion | C | — 5,307 sh | Apr 30, 2026 traded Apr 29, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Mark & Robyn Jones Descendants Trust 201410% Owner, Member of 10% owner group | GSHDGoosehead Insurance, Inc. Derivative conversion | C | — 5,307 sh | Apr 30, 2026 traded Apr 29, 2026 |
| 5 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Mark & Robyn Jones Descendants Trust 201410% Owner, Member of 10% owner group | GSHDGoosehead Insurance, Inc. Derivative conversion | C | — 5,307 sh | Apr 30, 2026 traded Apr 29, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Ladd Amy LDirector | ISRGINTUITIVE SURGICAL INC Option exercise | M | — 531 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Ball Robert JosephDirector, CEO & Executive Chairman |  SISHOULDER INNOVATIONS, INC.Option exercise | M | $25K 10.0K sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Ball Robert JosephDirector, CEO & Executive Chairman | SISHOULDER INNOVATIONS, INC. Option exercise | M | — 10.0K sh | Apr 30, 2026 traded Apr 30, 2026 |
| 2 | Coleman Denis P.Chief Financial Officer |  GSGOLDMAN SACHS GROUP INCOption exercise | M | — 19.2K sh | Apr 30, 2026 traded Apr 28, 2026 |
| 2 | Fredman Sheara JChief Accounting Officer | GSGOLDMAN SACHS GROUP INC Option exercise | M | — 14.2K sh | Apr 30, 2026 traded Apr 28, 2026 |
| 2 | Ring ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 2 |  Ruemmler Kathryn H.Chief Legal Officer, GC | GSGOLDMAN SACHS GROUP INC Option exercise | M | — 27.1K sh | Apr 30, 2026 traded Apr 28, 2026 |
| 1 | Coyne Terrance P.EVP & CFO |  RPRXRoyalty Pharma plcOpen-market sale · 10b5-1 plan | SELL | $93K 1,875 sh | Apr 30, 2026 traded Apr 28, 2026 |
| 0 | Intrator Michael NDirector, CEO and President, 10% Owner | CRWVCoreWeave, Inc. Derivative conversion · 10b5-1 plan | C | — 107.7K sh | Apr 30, 2026 traded Apr 28, 2026 |
